[go: up one dir, main page]

SG52464A1 - A novel compound form - Google Patents

A novel compound form

Info

Publication number
SG52464A1
SG52464A1 SG1996004887A SG1996004887A SG52464A1 SG 52464 A1 SG52464 A1 SG 52464A1 SG 1996004887 A SG1996004887 A SG 1996004887A SG 1996004887 A SG1996004887 A SG 1996004887A SG 52464 A1 SG52464 A1 SG 52464A1
Authority
SG
Singapore
Prior art keywords
novel compound
compound form
crystallinity
manufacture
useful
Prior art date
Application number
SG1996004887A
Other languages
English (en)
Inventor
Lars Ake Kallstrom
Monica Annelie Nygren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG52464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of SG52464A1 publication Critical patent/SG52464A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Conductive Materials (AREA)
  • Contacts (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Powder Metallurgy (AREA)
SG1996004887A 1993-07-09 1994-07-08 A novel compound form SG52464A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Publications (1)

Publication Number Publication Date
SG52464A1 true SG52464A1 (en) 1998-09-28

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004887A SG52464A1 (en) 1993-07-09 1994-07-08 A novel compound form

Country Status (42)

Country Link
US (1) US5900424A (ja)
EP (2) EP0707580B1 (ja)
JP (2) JP3635432B2 (ja)
KR (1) KR100353783B1 (ja)
CN (1) CN1064680C (ja)
AT (1) ATE212628T1 (ja)
AU (1) AU679766B2 (ja)
BR (1) BR9406940A (ja)
CA (1) CA2166794C (ja)
CZ (1) CZ288933B6 (ja)
DE (2) DE707580T1 (ja)
DK (1) DK0707580T3 (ja)
DZ (1) DZ1792A1 (ja)
EE (1) EE03127B1 (ja)
EG (1) EG21437A (ja)
ES (1) ES2100136T3 (ja)
FI (1) FI114154B (ja)
GR (1) GR970300015T1 (ja)
HK (1) HK1008329A1 (ja)
HR (1) HRP940385B1 (ja)
HU (1) HU226861B1 (ja)
IL (1) IL110190A (ja)
IS (1) IS2075B (ja)
MA (1) MA23257A1 (ja)
MX (1) MX9405217A (ja)
MY (1) MY113274A (ja)
NO (1) NO308702B1 (ja)
NZ (1) NZ268693A (ja)
PL (1) PL175999B1 (ja)
PT (1) PT707580E (ja)
RU (1) RU2139868C1 (ja)
SA (1) SA94150058B1 (ja)
SE (1) SE9302396D0 (ja)
SG (1) SG52464A1 (ja)
SI (1) SI0707580T1 (ja)
SK (1) SK281230B6 (ja)
TN (1) TNSN94079A1 (ja)
TW (1) TW504509B (ja)
UA (1) UA43343C2 (ja)
WO (1) WO1995001977A1 (ja)
YU (1) YU49193B (ja)
ZA (1) ZA944933B (ja)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
HUT78132A (hu) * 1994-07-08 2000-06-28 Astra Aktiebolag Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma
PT1078628E (pt) 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
PT1131316E (pt) * 1998-11-18 2004-10-29 Astrazeneca Ab Processo quimico e formulacao farmaceutica melhorados
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
EP1706397A4 (en) * 2000-05-15 2007-08-01 Ranbaxy Lab Ltd AMORPHOUS FORM OF OMEPRAZOLE SALTS
ATE342263T1 (de) 2000-08-04 2006-11-15 Takeda Pharmaceutical Salze von benzimidazol-derivaten und deren verwendung
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc NOVEL FORMULATION, ANTICIPATED COMPLEX IMMEDIATE RELEASE FOR A FAST AND CONTINUOUS SUPPRESSION OF MAGIC ACID
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
CA2531566C (en) * 2003-07-18 2013-05-07 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP2184058B1 (en) 2003-09-26 2012-02-08 ALZA Corporation Drug coating providing high drug loading and methods for providing the same
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
EP1830823A2 (en) 2004-12-23 2007-09-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
ES2511792T3 (es) 2006-07-25 2014-10-23 Vecta Ltd. Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2009132980A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
IS2075B (is) 2005-12-15
CZ6996A3 (en) 1996-05-15
AU679766B2 (en) 1997-07-10
JPH08512315A (ja) 1996-12-24
AU7198194A (en) 1995-02-06
CN1064680C (zh) 2001-04-18
YU49193B (sh) 2004-09-03
MX9405217A (es) 1995-01-31
US5900424A (en) 1999-05-04
NO960068D0 (no) 1996-01-05
DE69429774T2 (de) 2002-11-14
PL175999B1 (pl) 1999-03-31
DK0707580T3 (da) 2002-04-15
IS4186A (is) 1995-01-10
TW504509B (en) 2002-10-01
JP3878826B2 (ja) 2007-02-07
SE9302396D0 (sv) 1993-07-09
EP1164132A3 (en) 2002-01-02
MA23257A1 (fr) 1995-04-01
IL110190A0 (en) 1994-10-21
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
ZA944933B (en) 1995-02-20
TNSN94079A1 (fr) 1995-04-25
BR9406940A (pt) 1996-09-10
HRP940385B1 (en) 2003-06-30
GR970300015T1 (en) 1997-05-31
YU43694A (sh) 1997-07-31
ATE212628T1 (de) 2002-02-15
CA2166794C (en) 1997-03-04
DE707580T1 (de) 1997-09-04
PL312440A1 (en) 1996-04-29
HU226861B1 (en) 2009-12-28
FI960101A0 (fi) 1996-01-09
WO1995001977A1 (en) 1995-01-19
PT707580E (pt) 2002-06-28
EP0707580B1 (en) 2002-01-30
NZ268693A (en) 1997-05-26
RU2139868C1 (ru) 1999-10-20
SI0707580T1 (en) 2002-06-30
JP2002105072A (ja) 2002-04-10
NO308702B1 (no) 2000-10-16
JP3635432B2 (ja) 2005-04-06
EP0707580A1 (en) 1996-04-24
CZ288933B6 (cs) 2001-09-12
NO960068L (no) 1996-01-05
ES2100136T1 (es) 1997-06-16
DE69429774D1 (de) 2002-03-14
UA43343C2 (uk) 2001-12-17
HUT75314A (en) 1997-05-28
HRP940385A2 (en) 1997-02-28
FI114154B (fi) 2004-08-31
HU9503873D0 (en) 1996-02-28
MY113274A (en) 2002-01-31
IL110190A (en) 2000-07-26
EP1164132A2 (en) 2001-12-19
FI960101L (fi) 1996-01-09
EE03127B1 (et) 1998-10-15
CN1126993A (zh) 1996-07-17
KR100353783B1 (ko) 2004-04-03
DZ1792A1 (fr) 2002-02-17
EG21437A (en) 2001-10-31
ES2100136T3 (es) 2002-09-01
HK1008329A1 (en) 1999-05-07
SA94150058B1 (ar) 2006-06-20

Similar Documents

Publication Publication Date Title
GR970300015T1 (en) Magnesium omeprazole
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
HU9201518D0 (en) Process for the production of a medical composition
EP0404283A3 (de) 11-Beta-aryl-4-estrene, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AU661591B2 (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
HUT46664A (en) Process for producing new dihydropyridineamide derivatives and pharmaceutical compositions comprising these compounds
AU5778894A (en) Process for producing alkoxyiminoacetamide compounds and the production of intermediate compounds used in the process
HU904582D0 (en) Process for producing amino-oligohydroxi derivatives and pharmaceutical preparatives containing those compounds
HU903473D0 (en) Process for the production of beta-cyclodextrine based inclusion as a medical product
HU913404D0 (en) Process for the production of medical compositions
HU913658D0 (en) Process for the production of 1,2-dietoxybenzol of great clarity
HU913653D0 (en) Process for the industrial production of 5-alkyl-2'-dezoxy-beta-uridines by stereoselective synthesis
JO1822B1 (en) A new form of a compound
HU9201553D0 (en) New carbamide derivatives, process for their production and for the production of medical compositions containing them